Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 7/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305188 | 0.93 | MMP12 (0.57) | MMP12TP53THRBMAPTPKM | |
| SCHEMBL2953764 | 0.86 | MMP12 (0.64) | MMP12TP53THRBMAPTPKM | |
| SCHEMBL2955843 | 0.86 | MMP12 (0.54) | MMP12TP53THRBMAPTPKM | |
| SCHEMBL8303156 | 0.83 | MMP12 (0.57) | MMP12TP53THRBMAPTPKM | |
| SCHEMBL12060295 | 0.80 | TP53 (0.57) | MMP12TP53THRBMAPTPKM | |
| SCHEMBL3342717 | 0.80 | MMP12 (0.49) | MMP12TP53THRBMAPTPKM | |
| SCHEMBL5914785 | 0.80 | NR3C2 (0.51) | MMP12TP53THRBMAPTPKM | |
| SCHEMBL18264334 | 0.80 | MMP12 (0.49) | MMP12TP53THRBMAPTPKM | |
| SCHEMBL3342262 | 0.80 | MMP12 (0.57) | MMP12TP53THRBMAPTPKM | |
| SCHEMBL30015636 | 0.80 | MMP12 (0.49) | MMP12TP53THRBMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | MMP12 3383/4885TP53 1070/4885THRB 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.